Mabwell begins first-in-class Phase II trial of IL-11 antibody 9MW3811 for scarring in China

Mabwell (688062.SH) has announced that it has dosed the first patient in a Phase II clinical trial evaluating its anti-IL-11 monoclonal antibody, 9MW3811, for pathological scarring, positioning the Chinese biopharmaceutical company as the first in the world to initiate clinical testing of an IL-11 targeting therapy in this indication. The patient was enrolled at Shanghai Ninth People’s Hospital, a top-tier institution affiliated with Shanghai Jiao Tong University School of Medicine.

The trial represents a critical inflection point for Mabwell’s innovation strategy, offering potential entry into an area of significant unmet need—hypertrophic scars and keloids—where no approved biologic treatment currently exists. It also signals growing Chinese momentum in pushing first-in-class assets beyond preclinical fibrosis models into active dermatological intervention studies.

What does the Phase II trial of Mabwell’s anti-IL-11 antibody aim to prove in pathological scarring?

The Phase II trial (registry ID: CTR20254857) is designed to evaluate the safety, tolerability, pharmacokinetics, and early efficacy of 9MW3811 in patients with established pathological scarring. While Phase I trials conducted in both Australia and China have already demonstrated a favorable safety profile and a half-life exceeding one month, this Phase II study marks the first human trial of IL-11 inhibition in a fibrosis-focused, dermatological patient population.

Pathological scarring—manifesting as hypertrophic scars and keloids—remains a clinically and emotionally burdensome condition affecting millions worldwide. Treatment options today are largely palliative or invasive: corticosteroid injections, surgical excision, silicone therapy, or laser ablation, all of which offer limited or inconsistent long-term benefit. The lack of effective pharmacological interventions makes fibrosis a high-priority pathway for therapeutic innovation.

By targeting Interleukin-11 (IL-11), a pleiotropic cytokine implicated in organ fibrosis, tissue remodeling, and chronic inflammation, Mabwell aims to validate a new biological axis for dermal fibrotic modulation. IL-11’s role in driving fibroblast activation and collagen deposition has been increasingly supported in both pulmonary and hepatic fibrosis models. Its dermal relevance, however, is only now entering clinical exploration, with Mabwell’s program standing at the forefront.

How could IL-11 targeting reshape therapeutic options for hypertrophic scars and keloids?

If successful, 9MW3811 could become the first biologic intervention targeting the fibrotic cascade in dermal tissue, offering an alternative to the purely mechanical or anti-inflammatory modalities currently available. In preclinical studies, the antibody has shown promising efficacy across multiple fibrotic models, including pulmonary fibrosis and abnormal endometrial bleeding. Its most compelling dermatologic evidence comes from human-derived keloid xenograft models, where treatment with 9MW3811 was shown to reduce scar volume and attenuate fibrosis progression.

This development signals a broader attempt to pharmacologically reclassify scar formation as a treatable manifestation of chronic inflammation and dysregulated wound healing, rather than a cosmetic or post-surgical inevitability. While keloids are more common in specific ethnic populations, including Asian and African ancestries, the global prevalence and psychological impact of hypertrophic scarring remain widespread.

For Mabwell, this creates a dual strategic opportunity: lead a first-in-class therapeutic category and carve out a differentiated dermatology-fibrosis bridge that few Western biologics have attempted.

What makes 9MW3811 a strategic asset in Mabwell’s broader innovation portfolio?

9MW3811 is one of Mabwell’s self-developed biologics within its fully integrated industry chain—an end-to-end infrastructure that encompasses discovery, clinical development, manufacturing, and commercialization. The drug is emblematic of the company’s stated ambition to produce globally competitive assets that can compete beyond China’s borders.

From an innovation portfolio perspective, IL-11 inhibition offers a white-space opportunity. There are currently no marketed therapies in this class, and few known competitors pursuing IL-11 antibodies in advanced stages. This gives Mabwell a potential global first-mover advantage in not only pathological scarring but also broader fibrosis-linked conditions.

Mabwell’s previous disclosures indicate the company is also exploring indications such as pulmonary fibrosis and uterine bleeding, potentially leveraging 9MW3811’s broad anti-fibrotic and anti-inflammatory mechanisms across systemic and localized disorders. By anchoring the clinical program in dermatology—a field where visual endpoints and patient-reported outcomes are easier to capture—it may accelerate regulatory clarity and eventual market entry.

Moreover, Mabwell’s trial design in China strategically leverages the country’s accelerating regulatory frameworks, which have increasingly supported domestic innovation with fast-track status, priority review, and favorable pricing dynamics upon approval.

What competitive risk factors or execution challenges could impact trial success and commercial translation?

Several clinical and strategic risks remain. First, despite strong preclinical efficacy, there is no precedent for IL-11 inhibition as a validated therapeutic strategy in humans for any indication. The fibrosis field has seen numerous setbacks, with promising preclinical compounds failing to demonstrate meaningful effects in complex human tissues.

Second, the subjective nature of scar reduction outcomes—often influenced by skin type, location, previous interventions, and duration—could complicate efficacy assessments. Mabwell will need robust trial design, multi-modal imaging, and validated endpoints to persuade regulators and payers of therapeutic value.

Third, biologics for dermatological indications face pricing and reimbursement headwinds, particularly in markets where scars are not classified as a reimbursable medical condition but as cosmetic or elective treatments. Mabwell may need to pursue adjunct or combination strategies—such as surgical co-treatment—to strengthen the case for insurance coverage, especially outside China.

Finally, broader adoption of IL-11 inhibition would likely depend on expansion into high-burden fibrotic diseases like idiopathic pulmonary fibrosis or endometriosis, where the regulatory bar is higher and the competition more established.

What does this development signal about China’s biopharma push toward global-first innovation?

Mabwell’s Phase II milestone is part of a wider trend in Chinese biopharma to initiate not just me-too or fast-follower trials but first-in-class, mechanistically novel programs with global ambition. Recent pipeline advances across fibrosis, oncology, and inflammation signal that Chinese companies are increasingly designing programs that can compete on mechanistic novelty and clinical targeting, not just cost or manufacturing scale.

Furthermore, the integration of discovery, preclinical validation, and early-phase clinical trials within Chinese ecosystems is compressing timelines and reducing dependency on external partners. Mabwell’s ability to complete Phase I trials in both Australia and China and pivot quickly into Phase II in its home market exemplifies this agility.

While many Chinese biopharma firms still rely on licensing Western assets for revenue diversification, companies like Mabwell are positioning themselves as originators. Whether this model translates into regulatory success outside China remains to be seen, but the competitive intent is becoming harder to ignore.

Key takeaways on what Mabwell’s Phase II IL-11 antibody trial means for fibrosis drug development

• Mabwell has initiated Phase II trials of 9MW3811, the world’s first IL-11 targeting antibody, in patients with pathological scarring.

• The trial marks a first-in-class entry into fibrosis-linked dermatology, where no approved biologics exist for hypertrophic scars or keloids.

• 9MW3811’s mechanism targets IL-11, a cytokine implicated in tissue fibrosis across multiple organs, with preclinical efficacy in scar and fibrosis models.

• Mabwell’s integrated development and manufacturing strategy enables faster progression from discovery to clinical testing, leveraging China’s innovation-friendly regulatory framework.

• The company’s move into scar reduction opens new markets but also faces reimbursement and trial design complexity, especially for subjective dermatologic outcomes.

• Expansion into other fibrotic diseases could broaden the molecule’s value proposition, but clinical validation remains the key gating factor.

• Mabwell’s first-in-class claim reinforces China’s broader biopharma trend toward global innovation, not just local generics or biosimilars.

• Long-term success will depend on cross-border regulatory engagement, reproducibility of clinical benefit, and commercial pathway design for both cosmetic and therapeutic settings.